Stelara (Ustekinumab) clinical trials

OptIMMize-1: A Randomized, Active-controlled, Efficacy Assessor-blinded Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

This study is looking at how safe and effective new medicines, risankizumab and ABBV-066, are for young people aged 6 to under 18 with moderate to severe plaque psoriasis, compared to an existing treatment (Stelara).